<?xml version="1.0" encoding="UTF-8"?>
<p>In the United States, the FDA is accommodating emergent investigational application for the use of CP in patients with severe or immediate life-threatening SARS-CoV-2 infection, such as those in respiratory failure, septic shock and/or multiorgan failure (
 <xref rid="B113" ref-type="bibr">113</xref>).
</p>
